Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 13/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 3/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11952534 | 0.91 | DYRK1A (0.53) | DYRK1ADYRK1BCNR2 | |
| SCHEMBL4414669 | 0.89 | CNR2 (0.57) | DYRK1ADYRK1BCNR2PDE3BPDE3A | |
| SCHEMBL10318671 | 0.88 | DYRK1A (0.54) | DYRK1ADYRK1BCNR2 | |
| SCHEMBL10319867 | 0.88 | DYRK1A (0.54) | DYRK1ADYRK1BCNR2 | |
| SCHEMBL10319865 | 0.86 | DYRK1A (0.61) | DYRK1ADYRK1BCNR2 | |
| SCHEMBL10320719 | 0.85 | DYRK1A (0.52) | DYRK1ADYRK1B | |
| SCHEMBL10320590 | 0.84 | DYRK1A (0.49) | DYRK1ADYRK1BCNR2 | |
| SCHEMBL10320628 | 0.80 | SRD5A1 (0.67) | DYRK1ADYRK1BSMPD1 | |
| SCHEMBL10320741 | 0.79 | KDM4E (0.52) | DYRK1ADYRK1B | |
| SCHEMBL7222671 | 0.78 | SRD5A1 (0.65) | CNR2PDE3BPDE3ASMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191069-A1 | 2-oxoquinoline compounds and pharmaceutical uses thereof | JAPAN TOBACCO, INC (JP) | 2003-10-09 | — | — | US | claimed |
| US-6509352-B1 | Selectively act on cannabinoid receptors, particularly on peripheral type cannabinoid receptors, and have fewer side effects on the central nervous system, having great immunosuppressive action, anti-inflammatory action or | JAPAN TOBACCO INC. (JP) | 2003-01-21 | — | — | US | claimed |
| EP-1142877-A1 | 2-OXOQUINOLINE COMPOUNDS AND MEDICINAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2001-10-10 | — | — | EP | claimed |
| EP-2130820-A1 | Antipruritics | SHIONOGI & CO., LTD. (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-20080312292-A1 | Antipruritics | YASUI KIYOSHI | 2008-12-18 | — | — | US | disclosed |
| US-20050101590-A1 | Cannabinoid receptor agonists | SHIONOGI & CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1477186-A1 | ANTIPRURITICS | SHIONOGI & CO., LTD. (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-6806276-B2 | SIDE EFFECT REDUCTION ON CENTRAL NERVOUS SYSTEM; IMMUNOSUPPRESSANTS; ANTIINFLAMMATORY AGENTS; ANTIALLERGENS | JAPAN TOBACCO INC. (JP) | 2004-10-19 | — | — | US | disclosed |
| US-20030191069-A1 | 2-oxoquinoline compounds and pharmaceutical uses thereof | JAPAN TOBACCO, INC (JP) | 2003-10-09 | — | — | US | disclosed |
| US-6509352-B1 | Selectively act on cannabinoid receptors, particularly on peripheral type cannabinoid receptors, and have fewer side effects on the central nervous system, having great immunosuppressive action, anti-inflammatory action or | JAPAN TOBACCO INC. (JP) | 2003-01-21 | — | — | US | disclosed |
| EP-1142877-A1 | 2-OXOQUINOLINE COMPOUNDS AND MEDICINAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101590-A1 | Cannabinoid receptor agonists | CNR1, CNR2, OPRL1 | DYRK1A 798/4885DYRK1B 1075/4885CNR2 2/4885 |
| US-20030191069-A1 | 2-oxoquinoline compounds and pharmaceutical uses thereof | CNR2, CNR1, OPRL1 | DYRK1A 1592/4885DYRK1B 1792/4885CNR2 1/4885 |
| US-20080312292-A1 | Antipruritics | CNR1, CNR2, OPRL1 | DYRK1A 1576/4885DYRK1B 2160/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.